Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma

BACKGROUND It is desirable to prescribe the minimal effective dose of inhaled steroids to control asthma. To ensure that inflammation is suppressed whilst using the lowest possible dose, a sensitive and specific method for assessing airway inflammation is needed. METHODS The usefulness of exhaled ni...

Full description

Saved in:
Bibliographic Details
Published in:Thorax 1999-02, Vol.54 (2), p.108-114
Main Authors: Jatakanon, Anon, Kharitonov, Sergei, Lim, Sam, Barnes, Peter J
Format: Article
Language:English
Subjects:
Administration, Inhalation
Adult
airway inflammation
Asthma
Asthma - drug therapy
Asthma - pathology
Biological and medical sciences
Bronchodilator Agents - administration & dosage
Budesonide - administration & dosage
Cell Count
Dose-Response Relationship, Drug
Double-Blind Method
Eosinophils
Female
Forced Expiratory Volume - physiology
Humans
Inflammation
inhaled corticosteroids
Male
Medical sciences
Nitric Oxide - analysis
Original
Pharmacology. Drug treatments
Respiratory system
Sputum - chemistry
Steroids
Vital Capacity - physiology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND It is desirable to prescribe the minimal effective dose of inhaled steroids to control asthma. To ensure that inflammation is suppressed whilst using the lowest possible dose, a sensitive and specific method for assessing airway inflammation is needed. METHODS The usefulness of exhaled nitric oxide (NO), sputum eosinophils, and methacholine airway responsiveness (PC20) for monitoring airway inflammatory changes following four weeks of treatment with an inhaled corticosteroid (budesonide via Turbohaler) were compared. Mild stable steroid naive asthmatic subjects were randomised into two double blind, placebo controlled studies. The first was a parallel group study involving three groups receiving either 100 μg/day budesonide (n = 8), 400 μg/day budesonide (n = 7), or a matched placebo (n = 6). The second was a crossover study involving 10 subjects randomised to receive 1600 μg budesonide or placebo. The groups were matched with respect to age, PC20, baseline FEV1 (% predicted), exhaled NO, and sputum eosinophilia. RESULTS There were significant improvements in FEV1 following 400 μg and 1600 μg budesonide (11.3% and 6.5%, respectively, p
ISSN:0040-6376
1468-3296
DOI:10.1136/thx.54.2.108